bluebird bio, a clinical-stage biotechnology company focused on
transforming the lives of patients with severe genetic and orphan
diseases using gene therapy, announced today that James Mandell, M.D.
has joined the company’s board of directors. In addition, bluebird bio
announced that Axel Polack, Ph.D., general partner at TVM Capital
Partners, has stepped down from the board.
“The bluebird team is excited to welcome Dr Mandell to our board. Jim’s
clear passion for patients, in particular kids in need, is a perfect fit
with the company’s vision and culture. As the CEO of Boston Children’s
Hospital, Jim’s experience with the provider, payor and advocacy
community will be invaluable to bluebird bio as we advance our gene
therapy programs” said Nick Leschly, chief bluebird. “I would also like
to give a heartfelt thank you to Axel and the TVM team for their
steadfast commitment and guidance of bluebird over the years enabling
many of our recent accomplishments.”
Dr. James Mandell became Chief Executive Officer of Boston Children’s
Hospital and Children’s Medical Center on October 1, 2000, retiring from
the position in October 2013. During his tenure, Dr. Mandell was a
member of the Board of Trustees and Professor of Surgery at Harvard
Medical School. Prior to joining Children’s, he served as Dean of Albany
Medical College and Professor of Surgery and Pediatrics. Dr. Mandell was
promoted from Chief of Urology to Dean of Albany Medical College in
l996. He also served as Executive Vice President for Health Affairs at
Albany Medical Center and Executive Medical Director of Albany Medical
Center Hospital. Prior to his tenure at Albany Medical College, he was a
member of the medical staff at Children’s Hospital for nine years,
advancing to an associate in Surgery with an associate professor
appointment at Harvard Medical School. In addition to a medical degree
from the University of Florida College of Medicine, Dr. Mandell holds a
Master’s in Health Systems Management from Union College, New York.
Dr. Mandell serves on the Board of the Franciscan’s Hospital for
Children and as Chair of the Board of the Harvard Risk Management
Company.
About bluebird bio, Inc.
bluebird bio is a clinical-stage company committed to developing
potentially transformative gene therapies for severe genetic and orphan
diseases. bluebird bio has two clinical-stage programs in development.
The most advanced product candidate, Lenti-D, is in a recently-initiated
phase 2/3 study for the treatment of childhood cerebral
adrenoleukodystrophy (CCALD), a rare, hereditary neurological disorder
affecting young boys. The next most advanced product candidate,
LentiGlobin, is currently in a phase 1/2 study in France for the
treatment of beta-thalassemia major and severe sickle cell disease. A
second phase 1/2 study with LentiGlobin in the United States has been
initiated for the treatment of beta-thalassemia major.
bluebird bio also has an early-stage chimeric antigen receptor-modified
T cell (CAR-T) program for oncology in partnership with Celgene
Corporation.
bluebird bio has operations in Cambridge, Massachusetts and Paris,
France. For more information, please visit www.bluebirdbio.com
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the advancement of the Company’s gene therapy
programs. Any forward-looking statements in this press release
are based on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk of cessation or
delay of any of the ongoing or planned clinical studies and/or our
development of our product candidates, the risk of a delay in the
enrollment of patients in the Company’s clinical studies, the risk that
the results of previously conducted studies involving similar product
candidates will not be repeated or observed in ongoing or future studies
involving current product candidates, the risk that our collaboration
with Celgene will not continue or will not be successful, and the risk
that any one or more of our product candidates will not be successfully
developed and commercialized. For a discussion of other risks and
uncertainties, and other important factors, any of which could cause our
actual results to differ from those contained in the forward-looking
statements, see the section entitled "Risk Factors" in our most recent
quarterly report on Form 10-Q, as well as discussions of potential
risks, uncertainties, and other important factors in our subsequent
filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release, and
bluebird bio undertakes no duty to update this information unless
required by law.
Copyright Business Wire 2014